Kunshan RiboQuark Pharmaceutical Technology's Series A Round

Kunshan RiboQuark Pharmaceutical Technology raised a round of funding on January 08, 2014. Investors include BVCF.

Kunshan RiboQuark Pharmaceutical Technology is a joint venture between Suzhou Ribo Life Science Co. and Quark Pharmaceuticals to develop QPI-1007. QPI-1007 is a synthetic siRNA designed to temporarily…

Articles about Kunshan RiboQuark Pharmaceutical Technology's Series A Round: